Table 1.
Reference | Number of cases | Dose | Developmental stage | Age at treatment | Procedure | Clearance (ml/min/kg) | Notes |
---|---|---|---|---|---|---|---|
8 | 16 | Continuous infusion | 7 Preterm 9 Term | NA | Analgesia | NA | Morphine-3 sulfate present in urine Morphine-6 sulfate absent in urine Morphine sulfation negligible in neonates |
9 | 12 | Infusion | 5 Preterm 7 Term |
NA | Analgesia | NA | M-3G present in all patients M-6G present in 10 patients |
10 | 16 | Average dose 92±19 µg/kg |
Preterm 25-32 weeks g | <5 to 66 days (mean: 10) | Ventilation | NA | M-3G and M-6G found in two thirds of acutely ill preterm newborns |
11 | 49 | 20 µg/kg/h 30 µg/kg/h |
Term | 1 day to 2.5 years | Post-surgery | 5-21 | Morphine sulfate clearance equal to adult values at age 2-25 months |
12 | 17 | 100-200 µg/kg + infusion | Preterm (26-34 weeks) | 1 day | Analgesia | NA | M-3G detected in plasma on day 1 M-6G detected in plasma on day 1 |
13 | 10 | 100 µg/kg | Preterm (25-34 weeks) | 1 day | Analgesia | NA | Detected in plasma: Morphine Morphine-3-glucuronide at 2 hours Morphine-6-glucuronide at 24 hours |
14 | 35 | Dose adjusted to reach steady state: 20 ng/ml, 7-25 µg/kg/h | Term | 1-7 days 8-90 days 91-180 days 180-380 days |
Before and after cardiac surgery | 9.2-48.9 before surgery 5.5-21.7 after surgery |
M-3G detected from day 1 2 hours after dosing M-6G detected from day 2 |
15 | 31 | Dose adjusted through effect | Preterm Term | 10 days | Ventilation | Increase from 0.8-6.5 | To provide a rational basis for morphine administration |
16 | 68 | 10 µg/kg/h | Term | <7 days (52) >7 days (16) |
Major surgery | NA | To determine age-related differences in morphine needs |
M-3G: Morphine-3-glucuronide; M-6G: Morphine-6-glucuronide.